Vesencumab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A human IgG1 monoclonal antibody directed against neuropilin-1 (NRP1), with potential antiangiogenic and antineoplastic activities. Upon intravenous administration, vesencumab specifically targets and binds to NRP1; the antibody-NRP1 complex prevents the subsequent coupling of NRP1 to VEGFR2, thereby potentially inhibiting VEGF-mediated signaling and potentially preventing angiogenesis. In combination with other anti-VEGF therapies, vesencumab may enhance their anti-angiogenic effect. NRP1 is a membrane-bound co-receptor normally expressed by endothelial cells and overexpressed by certain tumor cells, and plays a role in angiogenesis, cell survival, migration, and invasion.

**Synonyms:** - Immunoglobulin GL, Anti-(Human Neuropilin 1) (Human Monoclonal MNRP1685a Heavy Chain), Disulfide with Human Monoclonal MNRP1685a Light Chain, Dimer - MNRP-1685A - MNRP1685A - VESENCUMAB